Role of CYP2C9 genetic variants for salt sensitivity and the regulation of the renin-angiotensin-aldosterone system in normotensive men

Journal of Hypertension

Volumn 29, Issue 1, 2011, Pages 56-61

  Bolbrinker, Juliane ^a   Beige, Joachim ^b   Huber, Matthias ^a   Sharma, Arya M ^c   Thomas, Alexander ^a   Deter, Hans Christian ^a   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Klinikum St Georg   (Germany)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

blood pressure; CYP2C9; genetics; renin angiotensin aldosterone system; salt sensitivity

Indexed keywords

ALDOSTERONE; CYTOCHROME P450 2C9; RENIN; SODIUM CHLORIDE;

ADULT; ALDOSTERONE BLOOD LEVEL; ALLELE; ARTICLE; BLOOD PRESSURE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; PHENOTYPE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE; SODIUM EXCRETION;

EID: 78650824842     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32833f5de5     Document Type: Article

References (34)

1. Natarajan R, Reddy MA. HETEs/EETs in renal glomerular and epithelial cell functions. Curr Opin Pharmacol 2003; 3:198-203.
2. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994; 94:2414-2420.
3. Capdevila JH, Falck JR, Imig JD. Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int 2007; 72:683-689.
4. Capdevila JH, Wei S, Yan J, Karara A, Jacobson HR, Falck JR, et al. Cytochrome P-450 arachidonic acid epoxygenase: regulatory control of the renal epoxygenase by dietary salt loading. J Biol Chem 1992; 267:21720-21726.
5. Holla VR, Makita K, Zaphiropoulos PG, Capdevila JH. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J Clin Invest 1999; 104:751-760.
6. Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension 2003; 42:775-780. (Pubitemid 37237324)
7. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD. Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension. Hypertension 2003; 41 (3 Pt 2):709-714.
8. Sankaralingam S, Desai KM, Glaeser H, Kim RB, Wilson TW. Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats. Am J Hypertens 2006; 19:1174-1180.
9. Liclican EL, Doumad AB, Wang J, Li J, Falck JR, Stier CT Jr, et al. Inhibition of the adenosine2A receptor-epoxyeicosatrienoic acid pathway renders Dahl salt-resistant rats hypertensive. Hypertension 2009; 54:1284-1290.
10. Enayetallah AE, French RA, Barber M, Grant DF. Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J Histochem Cytochem 2006; 54:329-335.
11. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52:447-454.
12. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54:1257-1270.
13. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2009; doi:10.1016/ j.tox.2009.08.013.
14. Donner KM, Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, Tikkanen I, Antikainen M, et al. CYP2C9 genotype modifies activity of the renin-angiotensin-aldosterone system in hypertensive men. J Hypertens 2009; 27:2001-2009.
15. Barlassina C, Dal FC, Lanzani C, Manunta P, Guffanti G, Ruello A, et al. Common genetic variants and haplotypes in renal CLCNKA gene are associated to salt-sensitive hypertension. Hum Mol Genet 2007; 16:1630-1638.
16. Sharma AM, Schattenfroh S, Thiede HM, Oelkers W, Distler A. Effects of sodium salts on pressor reactivity in salt-sensitive men. Hypertension 1992; 19 (6 Pt 1):541-548.
17. Schorr U, Sharma AM. Salt intake and left ventricular work load. J Hypertens 2000; 18:1721-1724.
18. Deter HC, Buchholz K, Schorr U, Mathiak K, Sharma AM. Salt-sensitivity and other predictors of stress-related cardiovascular reactivity in healthy young males. Clin Exp Hypertens 2001; 23:213-225.
19. Schorr U, Blaschke K, Turan S, Distler A, Sharma AM. Relationship between angiotensinogen, leptin and blood pressure levels in young normotensive men. J Hypertens 1998; 16:1475-1480.
20. Suarez-Kurtz G. Pharmacogenomics in admixed populations. Trends Pharmacol Sci 2005; 26:196-201.
21. Wei Y, Lin DH, Kemp R, Yaddanapudi GS, Nasjletti A, Falck JR, et al. Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways. J Gen Physiol 2004; 124:71 9-727.
22. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009; 41:1149-1160.
23. Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, et al. CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 2004; 348 (1 -2):57-61.
24. Joy MS, Dornbrook-Lavender K, Blaisdell J, Hilliard T, BoyetteT, Hu Y, etal. CYP2C9 genotype and pharmacodynamic responses to losartan in patients with primary and secondary kidney diseases. Eur J Clin Pharmacol 2009; 65:947-953.
25. Lajer M, Tarnow L, Andersen S, Parving HH. CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabet Med 2007; 24:323-325.
26. Stearns RA, Chakravarty PK, Chen R, Chiu SH. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: role of cytochrome P4502C and 3A subfamily members. Drug Metab Dispos 1995; 23:207-215.
27. Sekino K, Kubota T, Okada Y, Yamada Y, Yamamoto K, Horiuchi R, et al. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur J Clin Pharmacol 2003; 59 (8-9):589-592.
28. Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjoqvist F, et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002; 71:89-98.
29. Hong X, Zhang S, Mao G, Jiang S, Zhang Y, Yu Y, etal. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 2005; 61:627-634.
30. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, etal. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002; 20:2089-2093. (Pubitemid 35305508)
31. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure: age and pressure change over time. Hypertension 1991; 18:67-71.
32. Overlack A, Ruppert M, Kolloch R, Kraft K, Stumpe KO. Age is a major determinant of the divergent blood pressure responses to varying salt intake in essential hypertension. Am J Hypertens 1995; 8:829-836.
33. Anderson DE, Fedorova OV, Morrell CH, Longo DL, Kashkin VA, Metzler JD, et al. Endogenous sodium pump inhibitors and age-associated increases in salt sensitivity of blood pressure in normotensives. Am J Physiol Regul Integr Comp Physiol 2008; 294:R1248-R1254.
34. Liclican EL, McGiff JC, Falck JR, Carroll MA. Failure to upregulate the adenosine2A receptor-epoxyeicosatrienoic acid pathway contributes to the development of hypertension in Dahl salt-sensitive rats. Am J Physiol Renal Physiol 2008; 295:F1696-F1704.